Design of a complement mannose-binding lectin pathway-specific activation system applicable at low serum dilutions.
Recently we showed that alternative pathway (AP) amplification was responsible for more than 80% of specific classical pathway-induced terminal pathway activation under physiological conditions. The present study aimed to design a system for specific lectin pathway (LP) activation applicable at low serum dilutions with a fully functional AP. Comparison between activation of normal human serum (NHS), a mannose-binding lectin (MBL) homozygous D/D-deficient serum, and sera deficient in C1q and C2, all diluted 1 : 2, was essential to document optimal conditions for LP specificity. Mannan on the solid phase of enzyme-linked immunosorbent assay (ELISA) plates was used for activation, showing 0.5 microg mannan/well to give optimal conditions because at this concentration a good signal was preserved for C4 and TCC deposition in NHS, whereas the C3 deposition observed in C2-deficient serum at higher mannan concentrations reached nadir at 0.5 microg/well, indicating a lack of direct AP activation under these conditions. Pooled NHS and C1q-deficient serum gave the same degree of C4 and terminal complement complex (TCC) deposition, whereas deposition of these products was not obtained with MBL-deficient serum. Reconstitution with purified MBL, however, restored the depositions. A blocking anti-MBL monoclonal antibody (mAb) completely abolished the complement deposition, in contrast to a non-inhibiting anti-MBL mAb. Activation of C2-deficient serum induced C4 deposition similar to NHS, but negligible deposition of C3 and TCC, confirming the lack of direct activation of AP. Thus, this assay is unique in being LP-specific at low serum dilution and thus particularly suitable to study LP activation mechanisms and the role of AP amplification under physiological conditions.
Harboe
M
M
Institute of Immunology, University of Oslo and Rikshospitalet University Hospital, Oslo, Norway.
Garred
P
P
Borgen
M S
MS
Stahl
G L
GL
Roos
A
A
Mollnes
T E
TE
D000911:Antibodies, Monoclonal / Q000276:immunology; D015922:Complement C1q / Q000502:physiology; D003175:Complement C2 / Q000502:physiology; D003181:Complement C4 / Q000378:metabolism; D003170:Complement Pathway, Alternative / Q000502:physiology*; D037582:Complement Pathway, Mannose-Binding Lectin / Q000502:physiology*; D006801:Humans; D008351:Mannans / Q000276:immunology; D037601:Mannose-Binding Lectin / Q000276:immunology / Q000502:physiology*; D044967:Serum / Q000276:immunology
D000911:Antibodies, Monoclonal; D003175:Complement C2; D003181:Complement C4; D008351:Mannans; D037601:Mannose-Binding Lectin; D015922:Complement C1q